KRAS and gastric cancer: Advanced GC patients showed a greater frequency of cumulative genetic events, such as increased rates of PIK3CA mutations, better detection of immunotherapy biomarkers, and mutations of the estrogen receptor 1 (ESR1) gene, in addition to modifications of PIK3CA, KRAS, and ERBB2 as somatic oncogenic drivers [80].